INTRODUCTION
============

Unambiguous RNA resonance assignments and identification of a sufficient number of intermolecular NOEs is often one of the limiting factors preventing a rapid structure determination of protein--RNA complexes with NMR spectroscopy ([@b1],[@b2]). Reasons for this limitation originate from the severe resonance overlap that is present in RNA compared to proteins especially within the sugar protons of the RNA that all resonate within one p.p.m. except for the anomeric proton ([@b3]). To overcome this problem, methods based on *in vitro* transcription have been developed to isotopically label RNA with ^13^C and ^15^N and to facilitate RNA resonance assignments and the structure determination of RNAs and protein--RNA complexes ([@b4],[@b5]). Although, they have been successfully used to study RNA of 20 nt or more in size in complex with proteins ([@b1],[@b2]), labeling methods to produce short RNA oligonucleotides (2 to 10 in size) by *in vitro* transcription failed ([@b6]). Yet, isotopic labeling of short RNAs would be very useful to confidently assign the resonances of short RNAs in complex with proteins and to improve the precision of the resulting structures. Recently, three structures of proteins in complex with short single-stranded RNAs have been determined with NMR spectroscopy, namely SF1 ([@b7]), TIS~11d~ ([@b6]) and the Argonaute PAZ domain ([@b8]). All three were studied with unlabeled RNA making the resonance assignment of the RNA in complex very challenging, especially in the presence of an RNA with low sequence complexity like 5′-UUAUUUAUU-3′ used in the TIS~11d~--RNA complex ([@b6]).

Here, we report the synthesis of several short RNA sequences (4 to 7 nt) with \[^13^C~5~\]-labeled riboses at specific positions and their application for the resonance assignments and for the structure determination of two alternative-splicing factors, polypyrimidine tract binding protein (PTB) and feminizing locus on X (Fox-1), in complex with RNA. For this purpose, we evaluated and optimized the various reported synthetic methods ([@b9]--[@b12]) for the preparation of \[^13^C~5~\]-ribonucleosides from \[^13^C~6~\]-D-glucose. These intermediates were then converted into the corresponding 2′-*O*-\[(triisopropylsilyl)oxy\]methyl (= 2′-*O*-TOM) protected ribonucleoside phosphoramidites, which allows an efficient preparation of RNA sequences under DNA coupling conditions ([@b13],[@b14]). Chemical synthesis allows efficient ^13^C-labeling of very short RNAs and the possibility to introduce isotope-labeling at any position in the sequence, providing a fundamental advantage over isotope-labeling by *in vitro* transcription ([@b1],[@b2]). Using chemically synthesized ^13^C-labeled RNA, RNA resonance assignment was greatly facilitated as several ambiguities could be resolved. Also a very high number of intermolecular and intramolecular sugar--sugar NOE cross-peaks could be assigned permitting to obtain structures of very high precision ([@b15],[@b16]).

MATERIALS AND METHODS
=====================

General
-------

Reagents and solvents (highest purity) from various suppliers, used without further purification, unless otherwise stated. \[1,2,3,4,5,6--^13^C~6~\] glucose (^13^C \> 99%) from Spectra Stable Isotopes (Columbia, MD). Work up implies distribution of the reaction mixture between CH~2~Cl~2~ and saturated aqueous NaHCO~3~ solution, drying of the organic layer (MgSO~4~), and evaporation. TLC: pre-coated silica gel plates from Merck, stained by dipping into a solution of anisaldehyde (10 ml), H~2~SO~4~ (10 ml) and AcOH (2 ml) in EtOH (180 ml) and subsequent heating with a heat-gun. Column chromatography (CC): silica gel 60 (230--400 mesh) from Fluka. NMR (Bruker): chemical shift δ in p.p.m., relative to external standards (^1^H- and ^13^C: Me~4~Si, ^31^P: 85% aqueous H~3~PO~4~); coupling constants *J* in Hz; multiplicities (^13^C) according to DEPT-spectra. ESI-MS (positive mode): SSQ 710 (Finnegan), measurements in MeCN/H~2~O/AcOH 50:50:1; MALDI-MS (positive mode): Axima CFR Plus (Kratos/Shimadzu), matrix: 2,4,6-trihydroxyacetophenone (50 mg/ml), di-ammonium hydrogen citrate (15 mg/ml) in H~2~O/MeCN (1:1); relative intensity in % as indicated in brackets.

\[1,2,3,4,5--^13^C~5~\]-1,2-Di-*O*-acetyl-3,5-di-O-benzoyl-α,β-D-ribofuranose (1)
---------------------------------------------------------------------------------

Prepared essentially according to Saito *et al.* ([@b17]), for experimental details see Supplementary Data.

\[1′,2′,3′,4′,5′--^13^C~5~\]-6-Allyloxy-2-amino-*N*^2^-isobutyryl-5′-*O*-(4,4′-dimethoxytrityl)purine (3)
---------------------------------------------------------------------------------------------------------

A suspension of **1** (3.20 g, 7.15 mmol) and 2-amino-6-chloro-*N*^2^-isobutyrylpurine (2.06 g, 8.61 mmol) in (CH~2~Cl)~2~ (28 ml) was treated with *N,O*-bis(trimethylsilyl)acetamide (2.63 ml, 10.77 mmol). After 15 min at 65°C, TMS-OTf (4.53 ml, 25.13 mmol) was added and the mixture was stirred 30 min at 65°C. After usual work up, the intermediate **2** was dissolved in allyl alcohol (23 ml), treated with DABCO (1.21 g, 10.77 mmol) and DBU (1.61 ml, 10.77 mmol). After 1 h at 20°, the reaction mixture was diluted with CH~2~Cl~2~ (150 ml), extracted with 10% citric acid (200 ml), washed with saturated NaHCO~3~ (150 ml) and dried over MgSO~4~. After evaporation, the residue was dissolved in THF/MeOH 5:4 (180 ml), cooled to 0° and treated with 2N NaOH (18 ml). After 10 min at 0°, ion exchange resin IR 120 (H^+^ form, 30 ml) was added until the pH 7. The resin was filtered off and washed with THF/MeOH 5:4. The solvents were evaporated; the residue was co-evaporated with pyridine and dried under vacuum (0.01 mbar). The residue was dissolved in pyridine (30 ml) and treated with (MeO)~2~TrCl (2.9 g, 8.62 mmol). After 1 h at 20°, the reaction mixture was subjected to usual work up. CC \[75 g SiO~2~, CH~2~Cl~2~ (+2% NEt~3~) → CH~2~Cl~2~/MeOH 97:3 (+2% NEt~3~)\] gave **3** (3.26 g, 65%) as yellow foam. TLC (CH~2~Cl~2~/MeOH 9:1) *R*~f~ 0.58. ^1^H-NMR (^13^C decoupled, 400 MHz, CDCl~3~): 1.32, 1.34 (2*d, J* = 6.6, Me~2~CHCO); 2.62 (*heptett, J* = 6.8, Me~2~C*H*CO); 3.20 \[*d, J* = 9.7, H--C(5′)\]; 3.37 \[*d, J* = 10.2, H′--C(5′)\]; 3.45 (br. *s*, HO); 3.77 (*s*, 2 MeO); 3.79 (br. *s*, HO); 4.42 \[*m*, H--C(4′)\]; 4.50 \[*m*, H--C(3′)\]; 4.95 \[*s*, H--C(2′)\]; 5.09 (*d, J* = 5.4, OCH~2~CH=CH~2~);5.33 (*dd, J* = 10.4, 0.8, 1H, OCH~2~CH=C*H*~2~); 5.48 (*dd, J* = 17.3, 0.8 1H OCH~2~CH=C*H*~2~); 5.94 \[*d, J* = 5.2, H--C(1′)\]; 6.15, (*m*, OCH~2~C*H*=CH~2~); 6.68--6.75 (*m*, 4 arom. H); 7.09--7.40 (*m*, 9 arom. H); 7.46 \[br. *s*, HN-C(2)\]; 8.13 \[*s*, H--C(8)\]. ^13^C-NMR (100 MHz, CDCl~3~): 19.4 (*Me~2~*CHCO); 37.2 (Me~2~*C*HCO); 55.2 (MeO); 64.2 \[*d, J* = 42, C(5′)\]; 68.6 (O*C*H~2~CH=CH~2~); 72.2 \[*dd, J* = 38, C(4′)\]; 77.1 \[*dd, J* = 38, C(2′)\]; 87.4 \[*dd, J* = 41, C(3′)\]; 88.8 (arom. C); 92.6 \[*d, J* = 39, C(1′)\]; 113.5 (arom. CH); 119.2 (OCH~2~CH=*C*H~2~); 127.2, 128.2, 130.3, 130.4, 132.4 (5 arom. CH); 135.8, 135.9 (2 arom. C), 140.4 \[C(8)\]; 144.7 (arom. C); 151.5 \[C(6)\]; 152.0 \[C(2)\]; 158.88 (arom. C), 161.2 (arom. C); 175.7 (Me~2~CH*C*O). ESI-MS: 701.31 (100, \[*M* + H\]^+^).

\[1′,2′,3′,4′,5′--^13^C~5~\]-5′-*O*-(4,4′-Dimethoxytrityl)-*N*^2^-(isobutyryl)guanosine (4)
-------------------------------------------------------------------------------------------

A solution of **3** (3.44 g, 4.91 mmol) in CH~2~Cl~2~ (20 ml) was treated with Et~2~NH (1.28 ml, 12.3 mmol), PPh~3~ (296 mg, 1.13 mmol) and Pd(PPh~3~)~4~ (30 mg, 0.03 mmol). After 30 min at 20°, SiO~2~ (9 g) was added and the solvent was evaporated. The residue was purified by CC \[10 g SiO~2~, CH~2~Cl~2~ (+2% Et~3~N) → CH~2~Cl~2~/MeOH 95:5 (+2% Et~3~N)\]: **4** (2.90 g, 89%). TLC (CH~2~Cl~2~/MeOH 9:1) *R*~f~ 0.47. ^1^H-NMR (^13^C decoupled, 400 MHz, CDCl~3~): 0.81, 1.00 (2*d, J* ≈ 6, Me~2~CHCO); 2.83 (br. *q, J* ≈ 7, Me~2~C*H*CO); 3.19 \[*m*, H--C(5′)\]; 3.40 (br. *d, J* = 6.7, HO); 3.47 \[*m*, H′--C(5′)\]; 3.75, 3.76 (2*s*, 2 MeO); 4.31 \[*m*, H--C(4′)\]; 4.55 \[*m*, H--C(3′)\]; 5.14 \[*s*, H--C(2′)\]; 5.87 \[*d, J* = 5.2, H--C(1′)\]; 6.75--6.85 (*m*, 4 arom. H); 7.10--7.50 (*m*, 9 arom. H); 7.78 \[*s*, H--C(8)\]; 9.46 \[br. *s*, HN-C(2)\]; 12.16 \[br. *s*, H-N(1)\]. ^13^C-NMR (100 MHz, CDCl~3~): 18.5, 18.7 (Me~2~CHCO); 35.8 (Me~2~*C*HCO); 55.2 (MeO); 63.7 \[*d, J* = 43, C(5′)\]; \[71.5 (*t, J* = 38), 73.9 (*t, J* = 39), 85.1 (*t, J* = 41): C(2′), C(3′), C(4′)\]; 90.0 \[*d, J* = 41, C(1′)\]; 113.2 (arom. CH); 121.0 \[C(5′)\]; 126.9, 127.9, 128.1, 129.9, 130.0 (5 arom. CH); 135.7, 136.1 (2 arom. C); 138.9 \[C(8)\]; 144.7 (arom. C); 147.4 \[C(4)\]; 148.2 \[C(2)\]; 155.8 \[C(6)\]; 158.6 (arom. C); 179.7 (Me~2~CH*C*O). ESI-MS: 661.36 (100, \[*M* + H\]^+^).

\[1′,2′,3′,4′,5′--^13^C~5~\]-*N*^6^-Benzoyl-5′-*O*-(4,4′-dimethoxytrityl)adenosine (5)
--------------------------------------------------------------------------------------

A suspension of **1** (3.20 g, 7.15 mmol) and *N*^6^-benzoyladenine (2.05 g, 8.59 mmol) in (CH~2~Cl)~2~ (28 ml) was treated with *N*,*O*-bis(trimethylsilyl)acetamide (2.62 ml, 10.74 mmol). The mixture was stirred at 65°C for 15 min, treated with SnCl~4~ (2.9 ml, 25.06 mmol) and stirred 30 min at 65°C. After usual work up, the residue was dissolved in THF--MeOH 5:4 (250 ml), cooled to 0° and treated with 2N NaOH (25 ml). After 40 min at 0°, ion exchange resin IR 120 (H^+^ form, 30 ml) was added until the pH 7. The resin was filtered off and washed with THF--MeOH 5:4. The solvents were evaporated; the residue was co-evaporated with pyridine and dried under vacuum (0.01 mbar). The residue was dissolved in pyridine (30 ml) and treated with (MeO)~2~TrCl (3.20 g, 9.5 mmol). After 1 h at 20°, the reaction mixture was subjected to usual work up. CC \[75 g SiO~2~, CH~2~Cl~2~ (+2% NEt~3~) → CH~2~Cl~2~/MeOH 24:1 (+2% NEt~3~)\] gave **5** (3.79 g, 78%) as yellow foam. TLC (CH~2~Cl~2~/MeOH 9:1) *R*~f~ 0.44. ^1^H-NMR (^13^C decoupled, 400 MHz, CDCl~3~): 2.03 (br. *s*, HO); 3.35 \[*d, J* = 9.7, H--C(5′)\]; 3.48 \[*d, J* = 9.7, H′--C(5′)\]; 3.77 (*s*, 2 MeO); 4.42 \[*m*, H--C(4′)\]; 4.50 \[*m*, H--C(3′)\]; 4.93 \[*m*, H--C(2′)\]; 5.83 (br. *s*, HO); 6.10 \[*d, J* = 4.2, H--C(1′)\]; 6.75--6.79 (*m*, 4 arom. H); 7.16--7.38 (*m*, 9 arom. H); 7.49--7.69 (*m*, 3 arom. H); 8.02 (*d, J* = 7.3, 2 arom. H); 8.25 \[*s*, H--C(8)\]; 8.67 \[*s*, H--C(2)\]; 9.19 \[br. *s*, HN-C(6)\]. ^13^C-NMR (100 MHz, CDCl~3~): 55.2 (MeO); 63.5 \[*d, J* = 43, C(5′)\]; \[72.2 (*t, J* = 38), 75.4 (*dd, J* = 37, 40), 85.6 (*dd, J* = 39, 43): C(2′), C(3′), C(4′)\]; 86.5 (arom. C); 90.0 \[*d, J* = 41, C(1′)\]; 113.1 (arom. CH); 122.9 \[C(5)\]; 126.9, 127.7, 127.8, 127.9, 128.0, 128.3, 128.9, 129.1, 129.9 (9 arom. CH); 132.9, 135.4, 135.5 (3 arom. C); 141.6 \[C(8)\]; 144.4 (arom. C); 149.4 \[C(6)\]; 151.0 \[C(4)\]; 152.2 \[C(2)\]; 158.5 (arom. C); 164.7 (Ph*C*O). ESI-MS: 679.39 (100, \[*M* + H\]^+^).

\[1′,2′,3′,4′,5′--^13^C~5~\]-5′-*O*-(4,4′-Dimethoxytrityl)uridine (6)
---------------------------------------------------------------------

A suspension of **1** (1.70 g, 3.80 mmol) and uracil (0.52 g, 4.64 mmol) in MeCN (19 ml) was treated with *N*,*O*-bis(trimethylsilyl)acetamide (2.80 ml, 11.1 mmol) and stirred at 60°C for 30 min. Then, TMS-OTf (2.44 ml, 13.3 mmol) was added and the mixture was stirred 30 min at 60°C. After usual work up, the resulting intermediate was dissolved in 8 M MeNH~2~ in EtOH (19 ml) and stirred overnight at 20°. The solvent was evaporated; the residue was co-evaporated with pyridine and dried overnight under vacuum (0.01 mbar). The solid was dissolved in pyridine (19 ml) and treated with (MeO)~2~TrCl (1.80 g, 5.32 mmol). After 1 h at 20°, the reaction mixture was subjected to usual work up. CC (40 g SiO~2~, CH~2~Cl~2~ (+2% Et~3~N) → CH~2~Cl~2~/MeOH 19:1 (+2% Et~3~N)) gave **7** (1.49 g, 71%) as pink foam. TLC (CH~2~Cl~2~/MeOH 9:1) *R*~f~ 0.50. ^1^H-NMR (^13^C decoupled, 400 MHz, CDCl~3~): 3.48 \[*d, J* = 10.4, H--C(5′)\]; 3.55 \[*d, J* = 10.5, H--C(5′)\]; 3.79 (*s*, 2 MeO); 4.19 \[*d, J ≈* 4.1, H--C(4′)\]; 4.34 \[*m*, H--C(2′)\]; 4.43 \[*m*, H--C(3′)\]; 5.38 \[*d, J* = 8.1, H--C(5)\]; 5.92 \[br. *s*, H--C(1′)\]; 6.83--6.88 (*m*, 4 arom. H); 7.22--7.41 (*m*, 9 arom. H); 8.00 \[*d, J* = 8.1, H--C(6)\]. ^13^C-NMR (100 MHz, CDCl~3~): 55.2 (MeO); 61.8 \[*d, J* = 43, C(5′)\]; \[69.6 (*t, J* = 69), 75.4 (*dd, J* = 37, 41), 83.7 (*dd, J* = 43, 39): C(2′), C(3′), C(4′)\]; 86.9 (arom. C); 90.4 (*d, J* = 42), \[C(1′)\]; 102.2 \[C(5)\]; 113.2 (arom. CH); 127.1, 128.0, 128.1, 130.0, 130.1 (5 arom. CH); 135.1, 135.3 (2 arom. C); 140.4 \[C(6)\]; 144.3 (arom. C); 151.2 \[C(2)\]; 158.6 (arom. C); 163.9 \[C(4)\]. MALDI-MS: 574.5 (100, \[*M* + Na\]^+^).

\[1′,2′,3′,4′,5′--^13^C~5~\]-5′-*O*-(4,4′-Dimethoxytrityl)-*N*^2^-isobutyryl-2′-*O*-{\[(triisopropylsilyl)oxy\]methyl}guanosine (7), \[1′,2′,3′,4′,5′--^13^C~5~\]-*N*^6^-benzoyl-5′-*O*-(4,4′-dimethoxytrityl)-2′-*O*-{\[(triisopropylsilyl)oxy\]methyl}adenosine (8) and \[1′,2′,3′,4′,5′--^13^C~5~\]-5′-*O*-(4,4′-dimethoxytrityl)-2′-*O*-{\[(triisopropylsilyl)oxy\]methyl}uridine (9)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prepared essentially according to Pitsch *et al.* ([@b14]), for experimental details see Supplementary Data.

\[1′,2′,3′,4′,5′--^13^C~5~\]-*N*^4^-Acetyl-5′-*O*-(4,4′-dimethoxytrityl)-2′-*O*-{\[(triisopropylsilyl)oxy\]methyl}cytidine (10)
-------------------------------------------------------------------------------------------------------------------------------

Prepared according to Wenter *et al.* ([@b18]), for experimental details see Supplementary Data.

\[1′,2′,3′,4′,5′--^13^C~5~\]-*N*^2^-isobutyryl-5′-*O*-(4,4′-dimethoxytrityl)-2′-*O*-{\[(triisopropylsilyl) oxy\]methyl}guanosine 3′-(2-cyanoethyl diisopropylphosphoramidite) (11), \[1′,2′,3′,4′,5′--^13^C~5~\]-N^6^-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-O-{\[(triisopropylsilyl)oxy\]methyl} adenosine 3′-(2-cyanoethyl diisopropylphosphoramidite) (12), \[1′,2′,3′,4′,5′--^13^C~5~\]-5′-*O*-(4,4′-Dimethoxytrityl)-2′-*O*-{\[(triisopropylsilyl)oxy\]methyl}uridine 3′-(2-cyanoethyl diisopropylphosphoramidite) (13) and \[1′,2′,3′,4′,5′--^13^C~5~\]-*N*^4^-cetyl-5′-*O*-(4,4′-dimethoxytrityl)-2′-*O* {\[(triisopropylsilyl)oxy\]methyl}cytidine 3′-(2-cyanoethyl diisopropylphosphoramidite) (14)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prepared according to Pitsch *et al.* ([@b14]), for experimental details see Supplementary Data.

Solid supports
--------------

Prepared according to Pitsch *et al.* ([@b14]), for structures and experimental details see Supplementary Data.

Assembly and deprotection of RNA sequences S1--S6
-------------------------------------------------

The RNA sequences **S1**--**S6** were assembled from the ^13^C~5~-labeled phosphoramidites **11**--**14** and the corrresponding 2′-O-TOM protected, unlabeled phosphoramidites on a Gene Assembler Plus (Pharmacia) in a 1 μmol scale according to ([@b14]). After the assembly, the solid supports were treated with a 1:1 mixture of 12 [M]{.smallcaps} MeNH~2~ in H~2~O/8 M MeNH~2~ in EtOH (1 ml) for 3 h at 35°. By centrifugation, the supernatant solution was separated from the solid support and evaporated, and the residue was dissolved in 1 M Bu~4~NF·3 H~2~O solution in THF (1 ml). After 14 h at 20°, 1 M Tris--HCl buffer (pH 7.4, 1 ml) was added and the solution concentrated to half its volume.

Desalting and purification of RNA sequences r(^\[13C′5\]^Cp^\[13C′5\]^Up^\[13C′5\]^Cp^\[13C′5\]^U) (S1), r(Cp^\[13C′5\]^UpCp^\[13C′5\]^U) (S2), r(^\[13C′5\]^Up^\[13C′5\]^Cp^\[13C′5\]^Up^\[13C′5\]^Cp^\[13C′5\]^U) (S3) and r(^\[13C′5\]^UpCp^\[13C′5\]^UpCp^\[13C′5\]^U) (S4)
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The remaining solution from above (1 ml) was applied on a NAP-10 cartridge (Pharmacia) and eluted with H~2~O. Two fractions were collected: fraction 1 (1.5 ml) and fraction 2 (1 ml). Fraction 2 was again applied to a NAP-10 cartridge and eluted with H~2~O. The first 1.5 ml solution was combined with fraction 1 and purified by anion exchange--high-performance liquid chromatography (HPLC): Pharmacia Source 15Q column (4.5 × 100 mm), flow 2 ml/min, eluent A: 50 mM NEt~3~·H~2~CO~3~, eluent B: 1 M NEt~3~·H~2~CO~3~, detection at 260 nm, elution at 20°, gradient 0--45% B in 40 min, 1 injection. The fractions containing pure product were pooled and subjected to lyophilization. In order to completely remove the remaining NEt~3~·H~2~CO~3~, 0.5 ml H~2~O were added to the residue, followed by lyophilization (this procedure was carried out twice). The residue was dissolved in H~2~O (0.5 ml), treated with NaHCO~3~ (5 mg) and lyophilized twice. Final desalting on a NAP-10 cartridge was performed as described above, resulting in pure RNA sequences **S1**--**S4** as Na^+^ salts. Their amount was determined spectrophotometrically. **S1** (2 syntheses, 0.68 mg, 0.58 μmol, 29% yield), MALDI-MS (negative mode): 1182 a.m.u. \[*M*+H\]^+^; **S2** (2 syntheses, 0.66 mg, 0.56 μmol, 28% yield), MALDI-MS (negative mode): 1172 a.m.u. \[*M*+H\]^+^; **S3** (2 syntheses, 1.27 mg, 0.85 μmol, 43% yield), MALDI-MS (negative mode): 1493 a.m.u. \[*M*+H\]^+^; **S4** (2 syntheses, 1.26 mg, 0.85 μmol, 43% yield), MALDI-MS (negative mode): 1483 a.m.u. \[M+H\]^+^.

Desalting and purification of RNA sequences r(^\[13C′5\]^UpGp^\[13C′5\]^CpAp^\[13C′5\]^UpGpU) (S5) and r(Up^\[13C′5\]^GpCp^\[13C′5\]^ApUp^\[13C′5\]^Gp^\[13C′5\]^U) (S6)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The remaining solution from above (1 ml) was applied on a NAP-10 cartridge (Pharmacia) and eluted with H~2~O. The first 1.5 ml solution was purified by anion exchange--HPLC: Pharmacia Source 15Q column (4.5 × 100 mm), flow 2 ml/min, eluent A: 12.5 mM Tris--HCl (pH 7.5); eluent B: 12.5 mM Tris--HCl (pH 7.5), 1 M NaCl; detection at 260 nm, eluent at r.t., gradient 0--50% B in 45 min, two injections. Fractions containing pure product were treated with 1 M aqueous Et~3~N·H~2~CO~3~ to a final 0.1 M concentration and applied to a Sepak cartridge \[Waters, conditioned by washing with MeCN (10 ml) and 0.1 M aqueous Et~3~N·H~2~CO~3~ (10 ml)\]. The cartridge was washed with 20 mM Et~3~N·H~2~CO~3~ (10 ml) and the RNA sequences were eluted with MeCN/H~2~O 1:1 (4 ml). In order to completely remove the remaining NEt~3~·H~2~CO~3~, 0.5 ml H~2~O were added to the residue, followed by lyophilization (this procedure was carried out twice). The residue was dissolved in H~2~O (0.5 ml), treated with NaHCO~3~ (10 mg) and lyophilized twice. Final desalting on a NAP-10 cartridge was performed as described above, resulting in pure RNA sequences **S5** and **S6** as Na^+^ salts. Their amount was determined spectrophotometrically. **S5** (4 syntheses, 4.50 mg, 2.05 μmol, 51% yield), MALDI-MS (negative mode): 2197 a.m.u. \[M+H\]^+^; **S6** (4 syntheses, 3.43 mg, 1.56 μmol, 39% yield), MALDI-MS (negative mode): 2201 a.m.u. \[M+H\]^+^.

Preparation of protein, NMR-measurements, RNA resonance assignments and structure calculation
---------------------------------------------------------------------------------------------

The preparation of PTB and Fox-1 proteins and the related NMR-measurements are reported in Oberstrass *et al.* ([@b16]) and Auweter *et al.* ([@b15]), respectively. The structure calculation of the Fox-1 complex with the reduced set of NOE distance constraints from the unlabeled RNA sequence was performed in a restrained simulated annealing run using AMBER 7.0, following the same protocol that was employed for the structure calculation of the Fox-1 complex with the entire set of constraints; see ([@b15]).

RESULTS AND DISCUSSION
======================

Preparation of the ^13^C~5~-ribose-labeled ribonucleoside phosphoramidites
--------------------------------------------------------------------------

For the preparation of the four canonical, ^13^C~5~-ribose-labeled 2′-O-TOM protected ribonucleoside phosphoramidites and solid supports, we adapted and optimized existing reaction conditions with the purpose of minimizing the number of time-consuming purification steps ([Scheme 1](#sch1){ref-type="fig"}). The four-step synthesis of the protected ^13^C~5~-ribose derivative **1** from ^13^C~6~-labeled [d]{.smallcaps}-glucose (40% yield) was carried out essentially according to Saito *et al.* ([@b17]) and is described in the Supplementary Data. The protected adenosine and uridine derivatives **5** and **6** were obtained by nucleosidation of **1** with *N*^6^-benzoyladenosine (→ **5**) and uracil (→ **6**), respectively, under optimized *Vorbrüggen* conditions, followed by partial deacylation and dimethoxytritylation. The guanosine derivative **6** was prepared according to a modified method originally described for the synthesis of the corresponding ribopyranosylguanosine phosphoramidite by Pitsch *et al.* ([@b19]). In the presence of Me~3~SiOTf and in 1,2-dichloroethane, **1** reacted smoothly and completely regioselectively with *in situ* trimethylsilylated *N*^2^-isobutyryl-6-chlor-2-aminopurine to the purine derivative **2**. Without purification, it was treated with 1,4-diazabicyclo\[2,2,2\]octane (DABCO) and 1,8-diazabicyclo\[5,4,0\]undec-7-ene (DBU) in allyl alcohol, resulting in the corresponding *O*^6^-allyl derivative which was partially deacylated with NaOH in THF/MeOH/H~2~O and then dimethoxytritylated with (MeO)~2~TrCl in pyridine (→ **3**, 65% based on **1**). Cleavage of the *O*^6^-allyl group was achieved by treating the intermediate **3** with Et~2~NH in the presence of \[Pd(PPh~3~)~4~\], resulting in formation of the guanosine derivative **4** (89% yield).

The introduction of the 2′-*O*-TOM protecting group into nucleosides **4, 5** and **6** was carried out according to our standard procedure ([@b14]), with Bu~2~SnCl~2~, ^i^Pr~2~NEt and TOM-Cl in 1,2-dichloroethane at 80° (detailed procedure in Supplementary Data). The product mixture was separated into the 2′-*O*-TOM protected products **7**--**9**, the unreacted starting materials, and the 3′-*O*-TOM protected regioisomers. The latter were deprotected with Et~4~NF in MeCN, the products were combined with the unreacted starting materials and subjected again to alkylation with TOM-Cl. By this procedure, the 2′-*O*-TOM protected nucleosides **7**--**9** were obtained in fair yields of 42--50% ([Scheme 1](#sch1){ref-type="fig"}). From the 2′-*O*-TOM protected uridine **9**, the corresponding cytidine derivative **10** was obtained according to our published method ([@b18]), in a yield of 65%. Under standard conditions, the four 2′-*O*-TOM protected nucleosides **7**--**10** were converted with 2-cyanoethyl diisopropylphosphoramidochloridite/^i^Pr~2~NEt in CH~2~Cl~2~ into their corresponding phosphoramidite building blocks ([Scheme 1](#sch1){ref-type="fig"}). The solids supports were prepared according to ([@b14]) by first synthesizing the 2′-*O*-(nitrophenylheptane)dioates from the 3′-*O*-tom nucleosides of adenosine, uridine and cytosine and the 3′-*O*-(nitrophenylheptane)dioate from the 2′-*O*-TOM guanosine derivative. Then these activated esters were immobilized on 500 Å (aminoalkyl)-functionalized controlled pore glass (CPG) with loadings from 25 to 35 μmol/g (a detailed description for the preparation of phosphoramidites **7**--**14** and the corresponding solid supports is given in the Supplementary Data).

Chemical synthesis of the short ^13^C-labeled RNA oligonucleotides
------------------------------------------------------------------

The short and partially labeled RNA sequences **S1--S6** ([Table 1](#tbl1){ref-type="table"}) were assembled in 1 μM batches from conventional 2′-*O*-TOM protected ribonucleoside phosphoramidites and solid supports, and the corresponding ^13^C-labeled building blocks **11**--**14**, respectively, on an oligonucleotide synthesizer according to our standard protocols ([@b14]). The isolation and purification protocols of the shortest 4 and 5mer oligonucleotides **S1--S4** had to be modified, because of the small size and small number of negative charges present (for a detailed procedure see Materials and Methods). Finally, all RNA sequences were converted into their Na^+^ salts and characterized by MALDI-MS ([Table 1](#tbl1){ref-type="table"}).

NMR study of the ^13^C~5~-sugar labeled UCUCU and CUCU in complex with PTB
--------------------------------------------------------------------------

The oligo(CU) sequences **S1--S4** (Supplementary Table) containing ^13^C~5~-sugar labeled nucleotides at various positions were used for structure determination of PTB in complex with its target RNA sequence. We had to use these very short tetramers and pentamers, because PTB RBD1, RBD2 and RBD4 recognize only 3 nt and RBD3 only 5 nt ([@b16]). As illustrated in the ^13^C HSQC spectrum of **S3** bound to PTB RBD34 H134A, complete or partial ^13^C-labeling of the sugar moieties of these short RNAs allows resolving the strong proton resonance overlap in the sugar region of the RNA in complex with PTB ([Figure 1A)](#fig1){ref-type="fig"}. The RNAs containing only labeled uracils (**S2** and **S4**) were essential to confirm the resonance assignments of the bound RNAs ([Figure 1B](#fig1){ref-type="fig"}) and to unambiguously derive intermolecular NOEs between the sugar moiety and the protein side chains. Isotope-labeling of the RNAs was essential to this structure determination as 50 and 67% of the intermolecular NOEs involved RNA sugar resonances in the complex with RBD3 and RBD4 of PTB, respectively ([@b16]).

NMR study of the ^13^C~5~-sugar labeled UGCAUGU in complex with Fox-1
---------------------------------------------------------------------

The partially ^13^C-labeled RNA oligonucleotides **S5** and **S6** were used to determine the structure with Fox-1 ([@b16]). The two RNAs were essential to unambiguously assign the RNA resonances and to collect a high number of intra- and intermolecular NOE-derived constraints for UGCAUGU in complex with Fox-1. Without isotopically labeled RNA, the resonance assignment of the 7 nt RNA in complex was difficult and not unambiguous. While the proton resonances within each individual nucleoside could be linked using 2D NOESY and 2D TOCSY spectra, it was not possible to unambiguously place each individually assigned nucleotide spin-systems in the RNA sequence. In particular, we were doubtful about which spin-systems were corresponding to U5 and U7. With the 2D ^13^C HSQC spectra of the partially ^13^C-labeled RNA **S6** and **S7** in complex with Fox-1, these ambiguities could be solved, as **S6** contains a ^13^C~5~-labeled U5 and **S7** a ^13^C~5~-labeled U7 ([Figure 2A](#fig2){ref-type="fig"}). Importantly, with the particular labeling scheme present in **S6** and **S7**, in which ^13^C~5~-labeled and unlabeled nucleotides are present in alternation, unusual internucleotide sugar--sugar NOEs could be assigned using X-filter NOESY spectra ([@b20]) ([Figure 2B](#fig2){ref-type="fig"}). In total, 39 internucleotide sugar--sugar NOEs were assigned, which corresponds to 68% of the internucleotide constraints and one-third (31%) of the intra-RNA constraints. Only five of these internucleotide sugar--sugar NOEs could be assigned using an unlabeled RNA, the remaining 34 could only be resolved using labeled **S6** and **S7** due to ambiguity or resonance overlap. Similarly, of the 149 intermolecular distance constraints, which were used to calculate the Fox-1 complex structure, 83 originate from the sugar protons of the RNA and 57 of these could not have been assigned without the help of the labeled oligonucleotides ([@b15]). A structure calculation without the distance constraints from the ^13^C-labels resulted in a set of structures in which the RNA is significantly less defined: the RMSD of the heavy atoms of the RNA is 1.02 Å as compared to 0.55 Å in the case when all NOE distance constraints were included ([Figure 2C](#fig2){ref-type="fig"}). While each nucleotide is affected, the effect is strongest at the 5′ and 3′ terminal ends of the RNA. In particular, nucleotide U7 does not converge to one particular conformation ([Figure 2C](#fig2){ref-type="fig"}). Furthermore, the relative orientation of protein and RNA is less precise ([Figure 2C](#fig2){ref-type="fig"}). The complex structure of Fox-1 using all constraints is extraordinarily well defined, allowing a detailed analysis of the individual hydrogen bond, van der Waals and electrostatic interactions at the protein--RNA interface ([@b15]). In the structures obtained with the reduced set of constraints, an equal level of precision cannot be reached. Especially the intermolecular contacts to the RNA backbone are more heterogeneous. For example, a salt bridge between lysine 156 and the phosphate between G6 and U7 is observed in 28 of 30 structures ([Figure 2C](#fig2){ref-type="fig"}, left). In contrast, this salt bridge is observed in only 11 of the 30 structures obtained with the smaller number of NOE distance constraints ([Figure 2C](#fig2){ref-type="fig"}, middle). Hence, these NOEs were critical to determine with high precision the very unusual structure that the RNA adopts when bound to the RBD of Fox-1.

CONCLUSION AND PERSPECTIVES
===========================

In conclusion, we present a short and efficient synthetic access to 2′-*O*-TOM protected ribonucleoside phosphoramidites containing ^13^C-labeled sugar moieties. The site-specific introduction of these ^13^C-labeled nucleotides into RNA sequences permitted a straightforward and unambiguous resonance assignment of their complexes with PTB and Fox-1. The analysis of sets of RNA sequences with alternating labeling patterns allowed the assignments of numerous unusual sugar--sugar and intermolecular NOEs, which substantially improved the precision and accuracy of the resulting structures. Use of chemically synthesized ^13^C-labeled RNA sequences is likely to facilitate the study of single-stranded RNA binding proteins in complex with their target RNAs ([@b21]), particularly RNA binding proteins targeting low complexity or repeat sequences that are numerous in posttranscriptional gene regulation ([@b22]--[@b24]).
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Supplementary Material
======================

###### \[Supplementary Material\]

This work was supported by the EPFL, the NCCR 'Structural Biology' and the Swiss National Science Foundation (Grant No. 2000-06890) to S.P. and by the grants from the Swiss National Science Foundation and the ETH Zurich through the NCCR Structural Biology and by the Roche Research Fund for Biology at the ETH Zurich to F.H.T.A. F.H.T.A. is an EMBO Young Investigator. Funding to pay the Open Access publication charges for this article was provided by the EPFL.

*Conflict of interest statement*. None declared.

Figures and Tables
==================

![Preparation of the \[^13^C~5~\]-ribose-labeled 2′-*O*-TOM protected ribonucleoside phosphoramidites **11**--**14**. Abbreviations: Ac = acetyl, Bz = benzoyl, Ibu = isobutyryl, CE = cyanoethyl, DMT = (4,4′-dimethoxy)trityl, TOM = (triisopropylsilyl)oxymethyl. Reagents and conditions: (**a**) Adapted from Saito *et al.* ([@b17]), detailed procedure in Supplementary Data: 1. FeCl~3~, MgSO~4~, acetone, 20°; 2. pyridinium dichromate, Ac~2~O, CH~2~Cl~2~, reflux; 3. H~5~IO~6~, THF, 20°; 4. NaBH~4~, THF/EtOH 1:1, 20°; 5. BzCl, pyridine, 20°; 6. Ac~2~O, AcOH, H~2~SO~4~, 20°. (**b**) 6-Chloro-*N*^2^-isobutyrylpurine-2-amine, *N*,*O*-bis(trimethylsilyl)acetamide (BSA), Me~3~SiOTf, 1,2-dichloroethane, 65°. (**c**) 1. Allyl alcohol, DABCO, DBU, 20°; 2. NaOH, THF/MeOH/H~2~O, 0°; 3. DMT-Cl, pyridine, 20°. (**d**) Pd(Ph~3~P)~4~, HNEt~2~, PPh~3~, CH~2~Cl~2~, 20°. (**e**) Synthesis of **5**: 1. *N*^6^-benzoyladenine, BSA, SnCl~4~, 1,2-dichloroethane, 65°; 2. NaOH, THF/MeOH/H~2~O, 0°; 3. DMT-Cl, pyridine, 20°; synthesis of **6**: 1. uracil, BSA, Me~3~SiOTf, MeCN, 60°; 2. MeNH~2~, EtOH, 20°; 3. DMT-Cl, pyridine, 20°. (**f**) Bu~2~SnCl~2~, ^i^Pr~2~NEt, TOM-Cl, 1,2-dichloroethane, 80° according to ([@b14]). (**g**) 1. Ac~2~O, DMAP, pyridine 25°; 2. 4-chlorophenyl phosphorodichloridate, 1*H*-1,2,4-triazole, ^i^Pr~2~NEt, MeCN, 4° → 20°; 3. aqueous NH~3~, dioxane/MeCN, 20°; 4. NaOH, THF/MeOH/H~2~O, 4° 5. Ac~2~O, DMF, 20°, according to ([@b18]). (**h**) 2-Cyanoethyldiisopropylphosphoramidochloridite, ^i^Pr~2~NEt, CH~2~Cl~2~, 20°, according to ([@b14]).](gkl427s1){#sch1}

![(**A**) ^13^C HSQC spectra of UCUCU (**S3**) bound to PTB34 H134A (red). (**B**) ^13^C HSQC spectra of UCUCU (**S4**) bound to PTB34 H134A. In **S4**, only the uridines are ^13^C-labeled. The assignment is indicated and in spectrum (A), a cross indicates the position of the cross-peaks from cytidine resonances.](gkl427f1){#fig1}

![(**A**) ^13^C HSQC spectra of ∼1mM Fox-1 in complex with **S6** (red) or **S7** (blue). (**B**) Left: section of a 2D NOESY spectrum of ∼1 mM Fox-1 (unlabeled) in complex with UGCAUGU (unlabeled) showing the extreme overlap in the RNA sugar resonances. Middle left: the same section of a ω1, ω2-filtered 2D NOESY spectrum of ∼1 mM Fox-1 (uniformly ^13^C-labeled) in complex with UGCAUGU (unlabeled). In this spectrum, NOE cross-peaks arise only from intra-RNA correlations; overlap is reduced but assignments remain ambiguous. Middle right: the same section of a ω1-filtered, ω2-edited 2D NOESY spectrum of ∼1 mM Fox-1 (unlabeled) in complex with **S6**. NOE cross-peaks arise from correlations of protons attached to ^13^C (ω2) with protons attached to ^12^C (ω1). Right: the same section of a ω1-filtered, ω2-edited 2D NOESY spectrum of ∼1 mM Fox-1 (unlabeled) in complex with **S7**. NOE cross-peaks arise from correlations of protons attached to ^13^C (ω2) with protons attached to ^12^C (ω1). Underlined NOE assignments are displayed in the structure of the complex with green dashed lines in (**C**). Overlap and ambiguity are significantly reduced in the spectra with **S6** and **S7** and many internucleotide cross-peaks can be assigned due to the alternating labeling scheme. (C) Left: overlay of the 30 final structures of Fox-1 in complex with UGCAUGU calculated using the entire set of NOE distance constraints \[PDB code: 2ERR\] ([@b15]). Middle: overlay of the 30 final structures of Fox-1 in complex with UGCAUGU calculated using only those NOE distance constraints that could be assigned with unlabeled RNA oligonucleotides. The structures are superimposed on the heavy atoms of the RNA; the protein backbone is shown in black, the heavy atoms of the RNA are in red, and the side chains of F126 and K156 are in green and blue, respectively. Right: sections of one representative structure of the Fox-1-UGACUGU complex calculated using the entire set of NOEs. The protein backbone is depicted in ribbon representation (gray), aromatic protein side chains are shown in black, and the RNA is shown in red. Protons are displayed in gray.](gkl427f2){#fig2}

###### 

Preparation of selectively ^13^C-labeled RNA sequences

  Synthesis^a^                                                      Purification^b^ and MALDI-MS^c^              
  ----------------------------------------- -------- -------- ----- --------------------------------- ---------- ----------
                                            (μmol)   (μmol)   (%)                                     (a.m.u.)   (a.m.u.)
  S1: 5′-[CUCU]{.ul}-3′                     2        0.58     29    A                                 1182       1182
  S2: 5′-C[U]{.ul}C[U]{.ul}-3′              2        0.56     28    A                                 1172       1172
  S3: 5′-[UCUCU]{.ul}-3′                    2        0.85     43    A                                 1493       1493
  S4: 5′-[U]{.ul}C[U]{.ul}C[U]{.ul}-3′      4        0.85     43    A                                 1483       1483
  S6: 5′- [U]{.ul}G[C]{.ul}A[U]{.ul}GU-3′   4        2.05     51    B                                 2196       2197
  S7: 5′- U[G]{.ul}C[A]{.ul}U[GU]{.ul}-3′   4        1.56     39    B                                 2202       2201

^a^Preparation and deprotection of RNA-sequences according to *Pitsch et al.*(14); underlined letters in sequences indicate ^13^*C*~5~-ribose-labeled nucleosides.

^b^Purification and isolation: condition A: 1. Desalting on size-exclusion cartridges according to a modified protocol, 2. anion exchange--HPLC with aq. Et~3~N·H~2~CO~3~ gradients, 3. Removal of buffer by repeated lyophilization, 4. Transformation into Na^+^salt form by addition of NaHCO~3~, repeated lyophilization and desalting on size-exclusion cartridges; condition B: 1. Desalting on size-exclusion cartridges according to the standard protocol, 2. Anion exchange--HPLC with NaCl gradients, 3. Removal of eluent on C~18~-RP cartridges according to a modified protocol, 4. Transformation into Na^+^-salt form by addition of NaHCO~3~, repeated lyophilization and desalting on size-exclusion cartridges.

^c^Matrix: 2,4,6-trihydroxyacetophenone, di-ammonium citrate.
